Brief: Recce Pharmaceuticals Signs Middle East Licensing Term Sheet
27/05/2026 02:52
BRIEF-Recce Pharmaceuticals Signs Middle East Licensing Term Sheet May 27 (Reuters) - Recce Pharmaceuticals Ltd RCE.AX:
RECCE SIGNS MIDDLE EAST LICENSING TERM SHEET
10-YEAR EXCLUSIVE AGREEMENT INCLUDES UPFRONT FEE AND MILESTONES UP TO US$3.5 MILLION
TO RECEIVE 30% OF NET SELLING PRICE AND 6% ROYALTY ON SALES ABOVE US$50 MILLION/YEAR
SIGNS NON-BINDING TERM SHEET WITH LEADING MIDDLE EASTERN PHARMACEUTICAL COMPANY
PARTIES TARGET FINALISING DEFINITIVE LICENSING AGREEMENT NEXT QUARTER
LICENSEE TO RECEIVE EXCLUSIVE RIGHTS TO R327G IN KSA, GCC, EGYPT, ALGERIA, AND MOROCCO
Further company coverage: RCE.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Recce Pharmaceuticals
See all newsBrief: Recce Pharmaceuticals Signs Middle East Licensing Term Sheet
Australia's Reece Pharmaceuticals rises on research and development deal with US Army
Brief: Recce Pharmaceuticals Enters Second U.S. Department Of Defense Research And Development Agreement
Australia's Recce Pharmaceutical hits over 2-yr high on $3.5 million R&D tax rebate
Brief: Recce Pharmaceuticals Awarded Ausindustry Advanced Overseas Finding For Up To A$85M